Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Medicine (Baltimore) ; 102(13): e32662, 2023 Mar 31.
Artigo em Inglês | MEDLINE | ID: mdl-37000062

RESUMO

Pseudomonas aeruginosa infective endocarditis (IE) is a rare disease associated with high mortality and complications. Here, we describe a contemporary set of patients aiming to improve the understanding of risk factors, clinical features, treatments, and outcomes. This retrospective case series reviewed cases from 3 tertiary metropolitan hospitals between January 1999 and January 2019. prespecified data were collected for each case, with a review of risk factors, valve involvement, acquisition, treatment, and complications. Fifteen patients were identified over a 20 years period. All patients presented with fever, 5/15 had preexisting prosthetic valve with valvular heart disease in 7/15 patients making it the most common risk factor. Intravenous drug use (IVDU) was the source in only 6/15 cases with healthcare associated infection and left-sided valvular involvement being more common than previous reports both occurring in 9/15 cases. Complications occurred in 11/15 patients with a 30 days mortality of 13%. Surgery was performed in 7/15 patients and 9/15 patients received antibiotic combination therapy. One year mortality was higher in those with increasing age, comorbidities, left-sided valve involvement, presence of predefined complications, and antibiotic monotherapy. Development of resistance occurred in 2 cases that received monotherapy. P aeruginosa IE remains a rare disease with high mortality and secondary complications.


Assuntos
Endocardite Bacteriana , Endocardite , Humanos , Pseudomonas aeruginosa , Estudos Retrospectivos , Doenças Raras , Endocardite Bacteriana/diagnóstico , Endocardite Bacteriana/tratamento farmacológico , Endocardite Bacteriana/cirurgia , Endocardite/diagnóstico , Endocardite/tratamento farmacológico , Antibacterianos/uso terapêutico
2.
Infect Dis Health ; 25(4): 239-241, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-32763024

RESUMO

We report the first case of COVID-19 in a pregnant patient with cystic fibrosis. We describe the diagnosis, clinical course and management of the patient and their family with regards to clinical, social and infection control measures around delivery. This case highlights the importance of the cooperation of multidisciplinary teams to achieve good clinical outcomes in complex patients with COVID-19.


Assuntos
Infecções por Coronavirus/complicações , Fibrose Cística/virologia , Pneumonia Viral/complicações , Complicações Infecciosas na Gravidez/virologia , Adulto , Betacoronavirus/isolamento & purificação , COVID-19 , Infecções por Coronavirus/transmissão , Fibrose Cística/diagnóstico , Parto Obstétrico , Feminino , Humanos , Transmissão Vertical de Doenças Infecciosas , Masculino , Pandemias , Pneumonia Viral/transmissão , Gravidez , Complicações Infecciosas na Gravidez/diagnóstico , Complicações Infecciosas na Gravidez/fisiopatologia , Resultado da Gravidez , SARS-CoV-2 , Pessoas Transgênero
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA